August 11, 2017 / 3:21 PM / 8 days ago

BUZZ-Aeterna Zentaris Inc: Q2 revenue soars

** Canadian drug developer's U.S.-listed shares up as much as 33 pct to $2.30; second-biggest pct gainer on Nasdaq

** Q2 revenue rises to $243,000 from $96,000, helped by expanded contract for blood test Apifiny

** Apifiny is cancer-specific blood test to assess the risk of prostate cancer

** Says looking to evaluate various strategic and financing alternatives

** Up to Thursday's close, stock had fallen 51.9 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below